Avatar universal
IL28B polymorphisms predict interferon-related HBsAg seroclearance
IL28B polymorphisms predict interferon-related HBsAg serocl
Author: hbv_research-list-owners@mail-list.com
Date:  2012-04-10 04:02  +300
To: hbv_research
Subject: IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients
Hepatology. 2012 Apr 2. doi: 10.1002/hep.25749.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22473858
IL28B polymorphisms predict interferon-related HBsAg seroclearance in
genotype D HBeAg-negative patients with chronic hepatitis B.
Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V,
Soffredini R, Abrignani S, De Francesco R, Colombo M.
Source 1st Division of Gastroenterology, Fondazione IRCCS C? Granda
Ospedale Maggiore Policlinico, Universit? degli Studi di Milano, Milano,
Italy. pietro.***@****.
BACKGROUND.: Interleukin(IL)28B polymorphisms have been associated to
interferon(IFN)-induced viral clearance in patients with chronic
hepatitis C. Whether this is also true for patients with the difficult
to cure HBeAg-negative chronic hepatitis B, is unknown. METHODS.: 101
HBeAg-negative patients (92% genotype D) with compensated chronic
hepatitis B (84% males, 46 years, HBV DNA 6.0 log cp/ml, ALT 136 IU/L,
42% with cirrhosis) were followed for a median of 11 (1-17) years after
median 23 (10-48) months of either standard or pegylated (Peg)IFN alfa
therapy. A post-treatment response was defined as HBsAg clearance with
or without anti HBs seroconversion. The rs12979860 (C>T) genotype in the
IL28B locus was assessed in serum samples by using Custom TaqMan SNP
Genotyping Assays. RESULTS.: During a median of 11 years of
post-treatment follow-up, 21 (21%) patients cleared serum HBsAg,
including 15 who developed >10 IU/ml anti-HBs titers. Forty-eight
patients (47%) had CC genotype, 42 (42%) CT and 11 (11%) TT, the allelic
frequency being 68% for C allele and 32% for T allele.
The rate of serum HBsAg clearance was 29% (n=14) in CC compared to 13%
(n=7) in non-CC genotype carriers (p=0.039). Baseline HBV DNA levels 136 IU/ml (OR
6.5, CI 1.8-22.5, p=0.003), duration of IFN (OR 1.16, CI 1.02-1.31,
p=0.021) and genotype CC (OR 3.9, CI 1.1-13.2, p=0.025) independently
predicted HBsAg clearance. CONCLUSIONS.: IL28B polymorphism is an
additional predictor of off-therapy IFN-related HBsAg seroclearance to
be used in pretreatment stratification of HBeAg-negative patients
chronically infected by genotype D of hepatitis B virus. (HEPATOLOGY 2012.).
0 Answers
Page 1 of 1
Your Answer
Avatar universal
Do you know how to answer? Tap here to leave your answer...
Post Answer
Doctor Ratings & Reviews
Comprehensive info on 720K doctors.
Complete reviews, ratings & more.
Hepatitis B Community Resources